CN101406497A - Capparis spinosa extract as well as preparation method and application thereof - Google Patents

Capparis spinosa extract as well as preparation method and application thereof Download PDF

Info

Publication number
CN101406497A
CN101406497A CNA2008102033822A CN200810203382A CN101406497A CN 101406497 A CN101406497 A CN 101406497A CN A2008102033822 A CNA2008102033822 A CN A2008102033822A CN 200810203382 A CN200810203382 A CN 200810203382A CN 101406497 A CN101406497 A CN 101406497A
Authority
CN
China
Prior art keywords
nmr
chemical compound
extract
ppm
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008102033822A
Other languages
Chinese (zh)
Inventor
王长虹
王峥涛
杨涛
程雪梅
周吉燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI INSTITUTE CENTER OF STANDARDIZATION FOR TRADITIONAL CHINESE MEDICINE
Shanghai University of Traditional Chinese Medicine
Original Assignee
SHANGHAI INSTITUTE CENTER OF STANDARDIZATION FOR TRADITIONAL CHINESE MEDICINE
Shanghai University of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI INSTITUTE CENTER OF STANDARDIZATION FOR TRADITIONAL CHINESE MEDICINE, Shanghai University of Traditional Chinese Medicine filed Critical SHANGHAI INSTITUTE CENTER OF STANDARDIZATION FOR TRADITIONAL CHINESE MEDICINE
Priority to CNA2008102033822A priority Critical patent/CN101406497A/en
Publication of CN101406497A publication Critical patent/CN101406497A/en
Pending legal-status Critical Current

Links

Images

Abstract

The invention discloses caper extract and a preparation method thereof. The method comprises the following steps: medicinal materials are crushed, decocted in water or subjected to heating reflux extraction by utilization of ethanol with different concentrations, and added with the ethanol for impurity precipitation after concentration of extract; supernatant or more than 80 percent ethanol extract is subjected to concentration at reduced pressure; extract 1 is obtained after recovery of the ethanol, dried and dissolved in water, subjected to deesterification by utilization of petroleum ether, and extracted by ethyl acetate; an extracted position and a water-soluble position of the ethyl acetate are subjected to vacuum concentration and drying respectively and prepared into extract 2 and extract 3 respectively; the extract 1 contains 30 compounds including 5 novel compounds such as caper alkali A, and so on; the extract 2 contains 18 compounds such as a para hydroxybenzoic acid, and so on ; and the extract 3 contains 18 compounds including 5 novel compounds such as the caper alkali A, and so on. As proved by pharmacodynamic experiments, the extract 1, the extract 2 and the extract 3 have analgesic and anti-inflammatory activity, and can be used for preparing medicines for treating rheumatic arthritis, rheumatoid inflammation or scapulohumeral periarthritis.

Description

Capparis spinosa extract and preparation method thereof and application
Technical field
The present invention relates to Natural Medicine Chemistry, be specifically related to Capparis spinosa extract and preparation method thereof and the application in preparation treatment rheumatic arthritis, rheumatoid inflammation, scapulohumeral periarthritis medicine.
Background technology
Cortex Capparis Spinosae Radicis (Capparis spinosa L.) claims Cortex Capparis Spinosae Radicis, Herba hibisci trioni, mallet fruit rattan again, the dimension language claims " Pori gram fruit " or " chuck ", being that Capparidaceae (Capparidaceae) Chinese lime belongs to liana, is the drought-resistant plant that desert, half-desert, arid, the semiarid zone utmost point have cultivation to be worth.This plant mainly is distributed in Europe, North America, Oceania, western part of Asia, and all there is distribution provinces and regions such as Xinjiang of China, Gansu, the Inner Mongol, Tibet.China only produces 1 in husky district and belongs to a kind, and there is distribution in each husky district, Xinjiang, and is maximum with the Turpan Basin desert.Xinjiang Uygur its fresh fruit commonly used among the people is smashed diseases such as application treatment arthritis and scapulohumeral periarthritis to pieces, and its root bark has recorded in Drug Standard of Ministry of Public Health of the Peoples Republic of China Uigurs medicine fascicle (WS 3-BW-0050-98).
In some countries that are positioned at ring Mediterranean and West Asia, as Turkey, Italy, Spain, Morocco, Iran etc., the alabastrum of Cortex Capparis Spinosae Radicis is used as the spice of culinary art.As traditional drugs, the systematic study of Cortex Capparis Spinosae Radicis platymiscium chemical constituent is started from the 1950's, the chemical constituent that the Chinese lime of hitherto reported belongs to mainly contains sulfur glycoside, flavonoid, alkaloids, organic (phenol) acids, volatile oil and polysaccharide etc.Its pharmacologically active mainly includes anti-hepatotoxin effect, anti-high-blood-sugar function, effect for reducing blood fat, bacteriostasis, chondrocyte protective effect and antitumor action etc.Cortex Capparis Spinosae Radicis also is used to diuresis, resisting hypertension, external application for curing arthritis and strong preparation.
" chemical constitution study of Herba hibisci trioni fruit " [Harbin University of Commerce's journal natural science edition, 2005,21 (6): 684-686] and document " 1H-Indole-3 acetonitrile glycosides from Capparis spinosa fruits " [Phytochemistry, 1999,50:1205-1208] etc. bibliographical information, from the Cortex Capparis Spinosae Radicis fruit, separate obtaining: 6-Hydroxy-12-carboxy-blumenol A-D-glucopyranoside, 1H-indole-3-acetonitrile 4-O-beta-glucosidase, (6S)-Hydroxy-3-OXO-α-ionol, 3-aldehyde radical indole, adenosine, inosine, para Toluic Acid's rhamnitol glycosides, sucrose, composition such as cupreol and daucosterol.Document " Cortex Capparis Spinosae Radicis The Chemical Constituents " [Chinese herbal medicine, 2007,38 (4): 510-512] from the Cortex Capparis Spinosae Radicis fruit, separate and obtain wogonin (wogonin), oroxylin A (oroxylin A), nimbecetin (kaempferol), apigenin (apigenin), benzoic acid (benzoic acid), P-hydroxybenzoic acid (p-hydroxy-benzoicacid), hydroxy benzaldehyde (p-hydroxybenzaldehyde), cupreol (β-sitosterol), β-daucosterol (chemical constituent such as β-daucosterol).
Chinese patent 200610118369.8 discloses a kind of obtain extract and application thereof from the Cortex Capparis Spinosae Radicis medicinal part, this method comprises pulverizes the Cortex Capparis Spinosae Radicis medicinal part, reflux, merceration or percolation extract, concentrating under reduced pressure obtains crude extract, and crude extract is taken off ester with petroleum ether earlier, it is characterized in that the residue chloroform extraction after the defat, obtain extract.This extract contains cupreol, cupreol glucoside and 1-hydrogen-3-acetonitrile-base-4-methoxyl group-indole.The extract that contains above 3 kinds of compositions shows good effect to treatment rheumatic arthritis, rheumatoid arthritis and scapulohumeral periarthritis.
Chinese patent 200310113957.9 discloses a kind of method of extracting arthritis effective site from the plant Capparis fruit, with the Capparis fruit raw material pulverizing, ethanol or methanol heating and refluxing extraction with 50-90%, concentrating under reduced pressure, obtain crude extract, with the crude extract defat with petroleum ether, residue obtains containing the ethyl acetate and the n-butyl alcohol effective site of one or more Palmic acids or caffeic acid, coffee aldehyde or protocatechualdehyde respectively with ethyl acetate and n-butyl alcohol system eluting.This effective site has the effect of analgesia, antiinflammatory and inhibition immunity, is used for the treatment of rheumatic arthritis, rheumatoid arthritis, gout and scapulohumeral periarthritis disease.
But, patent 200610118369.8 and 200310113957.9 not deep enough in the research aspect chemical constituent, the present invention has carried out deep research to the composition for the treatment of rheumatic arthritis, rheumatoid arthritis, gout and scapulohumeral periarthritis disease in 3 kinds of extracts that prepare, there is more clearly understanding on basis to its effective ingredient, and has therefrom found 5 new chemical constituents.
Summary of the invention
Technical problem to be solved by this invention is to overcome above-mentioned weak point, the research Capparis spinosa extract, and use the method for gentle environmental protection and the method that solvent system prepares Capparis spinosa extract.
The invention provides a kind of Capparis spinosa extract.Extract of the present invention comprises extract 1,2 and 3.
Extract 1 of the present invention comprises following ingredients: capparisine A (1, capparisine A), Cortex Capparis Spinosae Radicis acid (2, cappariside A), capparisine B (3, capparisine B), capparisine C (4, capparisine C), capparisine D (5, capparisine D), P-hydroxybenzoic acid (6,4-hydroxybenzoic acid), protocatechuic acid (7, protocatechuic acid), vanillic acid (8, vanillic acid), former youngster's aldehyde (9, protocatechuic aldehy), syringic acid (10, syringic acid), 3,4-resorcylic acid (11,3,4-dihydroxybenzoate), fumaroyl (12, E-butenedioic acid), ethanedioic acid (13, succinic acid), 5 hydroxymethyl furfural (14,5-hydroxymethylfurfural), 5-methylol furancarboxylic acid (15,5-hydroxymethyl furoic acid), 2-furancarboxylic acid (16,2-furoic acid), dihydro-4 hydroxyls-5-methylol-2 (3H) furanone (17,4-hydroxy-5-(hydroxymethyl) dihydrofuran-2 (3H)-one), 7-hydroxy-2-oxoindolin-3-ylacetic acid (18), uracil (19, uracil), L-meso inositol (20, mesoinositol), uridnine (21, uridine), kaempferol rutin (22, kaempferol-3-O-rutinoside), β-daucosterol-6 '-stearate (23, β-sitosterylglucoside-6 '-octadecanoate), corchoionoside C (24), spionoside B (25), Herba Cleomis glycosides (26, glucocapperin), cupreol (27, β-sitosterol), β-daucosterol (28, β-daucosterol), rutin (29, rutin), indole-3-formaldehyde (30,1H-indole-3-carbaldehyde), comprising 5 noval chemical compounds, promptly chemical compound 1,2,3,4 and chemical compound 5.
Extract 2 of the present invention comprises following chemical components: chemical compound 6,7,18 chemical compounds such as 8,9,10,11,12,13,17,18,19,22,23,25,27,28,29,30 grades.
Extract 3 of the present invention comprises following chemical components: chemical compound 1,2, and 12 chemical compounds such as 3,4,5,14,15,16,20,21,24 and 26, wherein chemical compound 1,2, and 3,4,5 is noval chemical compound.Another object of the present invention provides a kind of preparation method of Capparis spinosa extract.
This method comprises the following steps:
(1), boils 2～3 times with 5～10 times of W/W decoctings of medical material, or, merge each time extracting solution with ethanol (50～95%) heating and refluxing extraction of 5～8 times of W/W of medical material 2～3 times with the Cortex Capparis Spinosae Radicis pulverizing medicinal materials;
(2) concentrated solution of decocting liquid adds ethanol (make contain the alcohol amount in the solution be 60～80%) precipitated impurities, precipitate with ethanol 2 times, remove precipitation, (50～80 ℃ of temperature, pressure 0.08～0.1MPa) get concentrated solution (density 1.03-1.1) behind the recovery ethanol to the supernatant concentrating under reduced pressure;
Or with the ethanol extract concentrating under reduced pressure of step (1) (50～80 ℃ of temperature, pressure 0.08～0.1MPa), concentrated solution (density 1.03-1.1);
(3) (50～80 ℃ of temperature get crude extract 1 to concentrated solution after pressure 0.08～0.1MPa) or the lyophilization through drying under reduced pressure;
(4) 1～3 times of amount of crude extract 1 usefulness crude extract W/W water, behind the dispersing and dissolving, take off ester 2～3 times with 1～1.5 times of amount V/V petroleum ether, measure the aqueous solution of V/V ethyl acetate extraction after taking off ester 2～3 times with 1～1.5 times, get ethyl acetate part and water-soluble portion, (30～50 ℃ of temperature are behind the pressure 0.08～0.1MPa) through concentrating under reduced pressure respectively for this two parts liquid, after decompression (vacuum) or lyophilization, make ethyl acetate extract 2 and water soluble part extract 3 again.
Extract 1 of the present invention, extract 2 and extract 3 all have antiinflammatory, analgesic activities preferably, and the strong and weak order of anti-inflammatory activity is extract 2＞extract 3＞extract 1; The strong and weak order of central analgesic activities is extract 2 〉=extract 1＞extract 3, and the strong and weak order of periphery analgesic activities is extract 3 〉=extract 1＞extract 2.
The separation of chemical constituent and structure are identified
Ethyl acetate extract 2 (60g) separates through silica gel (200～300 order) post, with dichloromethane-acetone (100: 0～5: 1), reuse dichloromethane-acetone (20: 1～0: 100) washes successively, and the sample that will get obtains 10 part A 1～10 after merging.With A2, A3, A4 and A5 adopt and mix silica gel on the sample method (200～300 order) post, and petroleum ether-ethyl acetate (5: 1) eluting separates obtaining chemical compound 6,7,8,9 respectively.A6 partly adopts and mixes silica gel on the sample method (200～300 order) post, with petroleum ether-ethyl acetate (5: 1) eluting, through column chromatography and recrystallization repeatedly, obtains chemical compound 10,11,12,13,14,17,18 and 19 again.In addition, A7 partly adopts silica gel column chromatography, with methylene chloride-methanol (15: 1) eluting, obtains chemical compound 22,23 and 25 through column chromatography repeatedly again.A7 partly adopts silica gel column chromatography, with methylene chloride-methanol (10: 1) eluting, obtains chemical compound 17,28,29 through column chromatography repeatedly again.
Water solubility extract 3 (100g) is gone up the C-18 reversed-phase column, with methanol-water (0: 1,1: 3,1.5: 1 and 95: 5) eluting, obtain B1～B4 part respectively, wherein B2 is again through silica gel column chromatography, Sephadex LH-20, and the ODS column chromatography separating purification obtains chemical compound 14,15,16,20,21,26.B3 is through silica gel column chromatography, Sephadex LH-20, and the ODS column chromatography separating purification obtains chemical compound 24,1, and 2,3,4,5.Wherein chemical compound 1,2, and 3,4,5 is noval chemical compound.
The structural formula of 30 kinds of chemical compounds is as follows:
Figure A20081020338200141
Figure A20081020338200151
Figure A20081020338200161
The spectral data of 30 kinds of chemical compounds
Numbering Title Spectral data
1 Capparisine A (capparisine A) 1H-NMR (DMSO-d 6, 500MHz) δ (ppm): 11.34bar (COOH), 9.34 (1H, s, CHO), 7.13 (1H, d, J=3.8Hz, H-8), 6.29 (1H, d, J=3.9Hz, H-9), 5.64 (1H, m, H-5), and 5.40m (1H, s, NH), 3.08 (1H, dd, J=9.2Hz, 17.0Hz, H-4a), 2.63 (1H, dd, J=6.6Hz, 17.0Hz, H-4b); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 179.0 (C-11), 175.2 (C-12), 175.1 (C-3), 125.8 (C-8), 144.9 (C-10), 131.3 (C-7), 109.7 (C-9), 54.8 (C-1), 54.7 (C-5), 37.3 (C-4).
2 Cortex Capparis Spinosae Radicis acid (cappariside), 1H-NMR (DMSO, 500MHz) δ (ppm): 7.93 (1H, s, H-2), 2.31 (3H, s, CH3); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 170.6 (COOH), 152.2 (C-4), 146.1 (C-3), 143.2 (C-5), 140.7 (C-2), 14.8 (CH 3).
3 Capparisine B (capparisine B) 1H-NMR (DMSO, 500MHz) δ (ppm): 9.54 (1H, s, CHO), 6.98 (1H, d, J=4.01Hz), 6.21 (1H, d, J=3.78Hz), 5.84 (1H, q, J=7.24Hz), 5.48 (1H, d, J=14.13Hz), 5.39 (1H, d, J=14.93Hz), (1.72 3H, d, J=7.27Hz CH3); 13C-NMR (CD3OD, 125MHz) δ (ppm): 179.7 (C-11), 168.1 (C-3),
130.8(C-6)，120.3(C-9)，124.0(C-7)，106.5(C-6)，63.3(C-1)， 53.8(C-4)，19.1(C-10)。
4 Capparisine C (capparisine C) 1H-NMR (DMSO, 500MHz) δ (ppm): 9.46 (1H, s, CHO), 6.93 (1H, d, J=3.69Hz, H-3), 6.03 (1H, d, J=3.52Hz, H-4), 4.96 (1H, d, J=15.35Hz, H-7a), 4.76 (1H, d, J=15.29 Hz, H-7b), 4.66 (1H, d, J=14.01Hz, H-6a), 4.34 (1H, d, J=13.58Hz, H-6b), 4.34 (1H, m, H-5 '), 4.25 (1H, m, H-4 '), 3.77 (1H, dd, J=2.49,12.29Hz, H-3 ' is a), 3.69 (1H, dd, J=3.64.49,11.87Hz, H-3 ' b), 2.27 (1H, m, H-6 '); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 178.9 (C-8), 134.6 (C-5), 131.2 (C-2), 124.2 (C-4), 105.0 (C-3), 104.1 (C-1 '), (89.7 C-1 '), (72.9 C-5 '), 62.9 (C-3 '), 58.0 (C-7), 50.3 (C-6), 44.9 (C-6 ').
5 Capparisine D (capparisine D) 1H-NMR (DMSO, 500MHz) δ (ppm): 9.45 (1H, s, CHO), 6.92 (1H, d, J=3.80Hz, H-7 '), 6.01 (1H, d, J=3.46Hz, H-8 '), 4.82 (1H, d, J=15.18Hz, H-1 ' a), 4.74 (1H, d, J=15.67Hz, H-1 ' b), 4.70 (2H, d, J=14.37Hz, H-4 ' a), 4.02 (1H, d, J=13.82Hz, H-4 ' b), 4.17 (1H, m, H-4), 3.88 (1H, s, H-5), 3.89 (1H, d, J=12.07Hz, H-6a), 3.81 (1H, d, J=12.07 Hz, H-6b), 2.04 (1H, dd, J=5.32,12.82Hz, H-3a), 1.91 (1H, t, J=12.43Hz, H-3b); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 178.8 (C-10 '), 134.1 (C-9 '), (131.2 C-6 '), (124.0 C-7 '), 104.8 (C-8 '), 95.4 (C-2), 67.4 (C-5), 65.1 (C-4), 64.5 (C-6), 57.8 (C-1 '), (52.2 C-4 '), 35.8 (C-3).
6 P-hydroxybenzoic acid (p-hydroxybenzcic acid) 1H-NMR (CD 3OD, 500MHz) δ (ppm): 7.78 (2H, d, J=8.8 Hz, H-3,5), 6.72 (2H, d, J=8.8Hz, H-2,6) are ortho position phenolic hydroxyl group hydrogen signal; 13C-NMR (CD 3OD, 125MHz) δ (ppm): 170.4 (C-7), 163.6 (C-4), 133.3 (C-2, C-6), 123.0 (C-1), 116.3 (C-3, C-5).
7 Protocatechuic acid (protocatechuic acid) 1H-NMR (CD 3OD, 500MHz) δ (ppm): 7.31 (1H, d, J=1.7 Hz, H-2), 7.2 (1H, dd, J=8.1,1.7Hz, H-6), 6.9 (1H, d, J=8.1Hz, H-5); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 170.7 (COOH), 151.8 (C-4), 46.3 (C-3), 124.2 (C-6), 123.5 (C-1), 118.1 (C-2), 116.1 (C-5).
8 Vanillic acid (vanillic acid) 1H-NMR (CD 3COCD 3, 500MHz) δ (ppm): 12.44 (1H, br.s, COOH), 9.81 (1H, br.s, OH), 7.46 (1H, dd, J=8.2,1.7 Hz, H-6), 7.43 (1H, d, J=1.7Hz, H-2), 6.77 (1H, d, J=8.2 Hz, H-5), 3.79 (3H, s, OCH3); 13C-NMR (CD 3COCD 3, 125MHz) δ (ppm): 167.5 (C-1), 152.1 (C-4), 148.1 (C-5), 124.9 (C-7), 122.9 (C-2), 115.5 (C-3), 113.5 (C-6), 56.4 (OCH 3).
9 Protocatechualdehyde (protocatechuic aldehyde) 1H-NMR (CD 3COCD 3, 500M Hz) and δ (ppm): 9.67 (s, 1H), 8.64 (2H, br.s, OH), 7.24 (1H, d, J=1.84Hz, H-2), 7.22 (1H, dd, J=8.03,1.86Hz, H-6), 6.87 (1H, d, J=8.01 Hz, H-5).
10 Syringic acid (syringic acid) 1H-NMR (500MHz, CD 3OD) δ (ppm): 7.20 (2H, s, H-2), 3.76 (6H, s, OCH3); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 167.5 (COOH), 148.4 (C-3,5), 141.6 (C-4), 121.5 (C-1), 108.2 (C-2,6), 56.7 (OCH 3).
11 3,4-dihydric ethyl benzoate (3,4-Ethyl Hydroxybenzoate) 1H-NMR (MeOD, 500MHz) δ (ppm): 7.37 (1H, d, J=2.0 HzH-2), 7.31 (1H, dd, J=2.0,8.3Hz, H-6), 6.76 (1H, d, J=8.3Hz, H-5), 4.13 (2H, q, OCH 2), 1.19 (3H, t ,-CH 3); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 166.6 (C=O), 150.7 (C-4), 145.6 (C-3), 123.3 (C-1,6), 122.9 (C-2,1), 117.2 (C-5), 115.7 (C-2), 60.8 (OCH 2), 14.6 (CH 3).
12 Fumaric acid (fumaric acid) 1H-NMR (CD 3OD, 500MHz) δ (ppm): 6.81 (1H, d, J=15.8 Hz, H-2), 6.48 (1H, d, J=15.8Hz, H-3); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 134.8 (C-2, C-3), 166.1 (C-1, C-4).
13 Succinic acid (butanedioic acid) 1H-NMR (CD 3OD, 500MHz) δ (ppm): 2.5 (4H, d, J=15.8Hz, H-2,3); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 176.5 (C-1, C-4), 30.1 (C-2, C-3).
14 5 hydroxymethyl furfural (5-hydroxymethyfu rfural) 1H-NMR (MeOD, 400MHz) δ (ppm): 11.16 (1H, s, COOH), 7.78 (1H, d, J=0.82Hz, H-3), 7.22 (1H, dd, J=3.32,0.36 Hz, H-5), 6.62 (1H, dd, J=3.33,1.73Hz, H-4); 13C-NMR (MeOD, 125MHz) δ (ppm): 159.4 (C-1 '), 147.6 (C-5), 145.9 (C-2), 118.6 (C-3), 112.7 (C-4).
15 5-methylol furancarboxylic acid (5-hydroxymethyl furoic acid) 1H-NMR (CD 3OD, 500M Hz) δ (ppm): 7.06 (1H, d, J=3.42 Hz, H-3), 6.36 (1H, d, J=3.43Hz, H-4), 4.47 (3H, s, H 2); 13C-NMR (CD 3OD, 125MHz) δ (ppm): 162.08 (C-2 '), 160.99 (C-2), 45.99 (C-5), 120.28 (C-3), 110.51 (C-4), 57.8 (C-5 ').
16 2-furancarboxylic acid (2-furoic acid) 1H-NMR (MeOD, 400MHz) δ: 11.16 (1H, s, COOH), 7.78 (1H, d, J=0.82Hz, H-5), 7.22 (1H, dd, J=3.32,0.36Hz, H-3), 6.62 (1H, t, J=3.33,1.73Hz, H-4); 13C-NMR (MeOD, 125MHz) δ: 159.41 (s, C-1 '), 147.61 (s, C-5), 145.96 (s, C-2), 118.62 (s, C-4), 112.71 (s, C-3).
17 Dihydro-4 hydroxyls-5-methylol-2 (3H) furanone (4-hydroxy-5-(hydr o-xymethyl) dihydro furan-2 (3H)-one) 1H-NMR (MeOD, 500MHz) δ: 4.42 (1H, m, 5-H); 4.36 (1H, t, J=2.2Hz, J=3.5Hz, 4-H); (3.76 1H, dd, J=12.4Hz, J=3.3Hz 6-H); 3.68 (1H, dd, J=12.5Hz, J=3.6Hz, 6-H); 2.91 (1H, dd, J=18Hz, J=6.8Hz, 3-H); 2.37 (1H, dd, J=17.8Hz, J=2.6Hz, 3-H); 13C-NMR (MeOD, 125MHz) δ: 178.9 (C-2), 90.5 (C-5), 69.9 (C-4), 62.8 (C-6), 39.4 (C-3).
18 7-hydroxy-2-oxoin dolin-3-ylacetic acid 1H-NMR(MeOD，500MHz)δ：6.76(1H，t，J＝7.67，H-5)； 6.72(1H，dd，J＝1.1，7.52Hz，H-4)；6.66(1H，dd，J＝7.69， 1.5Hz，H-6)；3.81(1H，dd，J＝3.45Hz，6.41Hz，H-3)； 2.75(1H，dd，J＝16.44，J＝3.46Hz，H-11)；2.66(1H，dd， J＝16.44，J＝6.57Hz，H-11)； 13C-NMR(MeOD，125MHz)δ： 175.9(C-11)，172.0(C-2)，145.8(C-7)，126.8(C-8)，124.6(C-5)， 123.5(C-9)，121.0(C-4)，115.8(C-6)，44.0(C-3)，34.4(C-10)。
19 Uracil 1H-NMR (DMSO d 6, 500MHz) δ: 13.11 (1H, s), 12.43 (1H,
(uracil) s)，7.59(1H，d，J＝7.56Hz)，5.88(1H，d，J＝7.57Hz)。 13C-NMR(DMSO-d 6，125MHz)δ：165.9(C-4)，153.3(C-2)， 101.4(C-5)，142.2(C-6)。 1Proton signal δ on the H-NMR H13.11 (1H, s), 12.43 (1H s) is the signal of active proton, δ H7.59 (J=7.5H7), 5.40 (1H, d J=7.5Hz) are the olefinic proton signal for 1H, d. 13C-NMR spectrum shows 4 carbon signals: 165.9,153.3,142.2,101.4 respectively ownership be the carbon signal of unsaturated amides, urea groups and two keys.
20 Meso inositol (mesoinositol) 13C-NMR (DMSO, 400MHz) δ C: 74.3,72.4,72.2,71.1, all be to connect oxygen carbon, δ C: 72.4,71.1 two carbon signal peaks are higher, illustrate that they are respectively two carbon signals, and chemical compound should be hexa-atomic cyclic alcohol. 1H-NMR (DMSOO, 400MHz): δ 4.52 (1H, d, J=3.72Hz) δ 4.46 (1H, d, J=4.19Hz), and δ 4.44 (2H, d, J=3.07Hz), δ 4.32 (2H, d, J=5.43Hz), δ 3.70 (1H, d, J=2.68Hz), and δ 3.37 (1H, dd, J=2.68.9.34Hz), δ 3.11 (2H, m), 2.90 (1H, td, J=9.1,4.07 Hz) from their coupling constant, there is a hydrogen to be in the e key, other five hydrogen all are in a key.
21 Uridnine (uridine) 1H-NMR (DMSO d 6, 400MHz) δ: 7.98 (1H, d, J=8.1Hz, H-6), 5.89 (1H, d, J=4.6Hz, H-1 '), be sugared terminal hydrogen signal, because of coupling constant is 4.6, be indicated as the α configuration, 5.69 (1H, d, J=8.1, H=8.1Hz, H-5), 3.7～4.2, be the hydrogen signal on the sugar. 13C-NMR (DMSO-d 6. 400MHz) δ: 166.5 (C-4), 152.8 (C-2), 143.0 (C-6), 91.0 (C-5), be the carbon signal of uracil, 102.9 is sugared end group carbon signal, other δ 86.6,76.0,71.6 62.6 are the carbon signal of sugar, are pentose.
22 Kaempferol 3-O-rutin (kaempferol-3-O-rutinoside) 1H-NMR (DMSO-d, 500MHz) δ: 12.56 (5OH), 10.80 (1H, br s, OH), 10.09 (1H, br s, OH), 7.98 (2H, d, J=8.6Hz, IH-2 ', 6 '), 6.87 (2H, d, J=8.6Hz, H-3 ', 5 '), 6.41 (1H, s, H-8), 6.20 (1H, s, H-6), 5.31 (1H, d, J=7.3Hz, H-1 ", of glucose), 4.38 (1H; brs, H-rhamnose), 0.99 (3H, d, J=6.1Hz, rha-CH3); 13C-NMR (DMSO-d, 125MHz) δ: 177.3 (C-4), 164.1 (C-7), 161.2 (C-5), 159.8 (C-4 '), 156.8 (C-9), 156.4 (C-2), 133.1 (C-3), 130.8 (C-2 ', 6 '), 120.9 (C-1 '), 115.0 (C-3 ', 5 '), 103.9 (C-10), 101.3 (C-1 "); 100.7 (C-1 " '), 98.7 (C-6), 93.7 (C-8), 76.3 (C-3 "), 75.7 (C-5 "), 74.1 (C-2 "); 71.8 (C-4 " '), 70.6 (C-3 " '), 70.3 (C-4 "), 69.9 (C-2 " '); 68.2 (C-5 " '), 66.8 (C-6 "), 17.7 (C-6 " ').
23 β-daucosterol-6 '-stearate (β-sitosterylglucosi de-6 '-octadecanoate) 1H-NMR (CDCl3,500MHz) δ: 0.65 (3H, s, C 18-H), 0.80-0.98 (m, CH 3), 1.25 (bra, CH 2), 1.47-2.00 (CH 2And CH), 2.34 (2H, t, J=7.5Hz, CH2COO), 3.36 (1H, m, C3-H), 3.51-4.37 (m, the hydrogen on the sugar), 5.34 (1H, m, C6-H). 13C-NMR(CDCl3，125MHz) δ：174.2，140.4，122.1，101.3，79.8，76.2，73.8，73.4， 70.5，63.6，56.8，56.2，50.2，45.9，42.4，39.8，38.9，37.3， 36.7，36.2，34.3，33.9，31.9，31.9，29.7-29.8，29.5，29.34， 29.34，29.3，29.2，28.3，26.3，25.0，24.32，23.1，22.7， 21.1，19.8，19.05，18.80，14.10，11.98，11.87。
24 6，9-Dihydroxy-4，7- 1H-NMR(MeOD-d 6，500MHz)δ：5.78(1H，s，H-5)，5.70(2H，
megastigmadien-3- onel m，H-6，7)，4.22(1H，dq，J＝6.4，4.4Hz，H-9)，2.41(1H， d，J＝16.8Hz，H-a)，2.06(1H，d，J＝16.9Hz，H-2β)，1.82 (1H，d，J＝1.2Hz，H-13)，1.14(3H，d，J＝6.5Hz，H-10)， 0.94(3H，s，H-11)，0.91(3H，s，H-12)。 13C-NMR δ：201.5(C-3)， 167.7(C-5)，137.3(C-7)，130.4(C-7)，130.3(C-8)，127.4(C-4)， 80.3(C-6)，69.0(C-9)，51.1(C-2)，42.7(C-1)，24.8(C-12)， 24.1(C-11)，23.8(C-4)，19.8(C-13)。
25 spionoside B 1H-NMR(DMSO-d6，500MHz)δ：6.26(1H，d，J＝15.26Hz， H-7)，5.94(1H，dd，J＝15.25，6.11Hz，H-8)，4.75(OH)， 4.48(1H，dq，J＝6.27，6.36Hz，H-9)，4.14(1H，d，J＝7.64 Hz，H-1′)，3.75(2H，dd，J＝7.32，2.49Hz，H-11a)，3.49(1H， d，J＝7.39Hz，H-11b)，3.63(1H，m，H-6′a)，3.38(1H，m， H-6′b)，2.9～3.1(4H，m，H-2′，3′，4′，5′)，2.27(d，J＝17.47 Hz，H-4a)，2.71(d，J＝17.2Hz，H-4b)，2.67(dd，J＝16.78， 1.54Hz，H-2a)，2.22(d，J＝17.59Hz，H-2b)，1.22(d，J＝6.49 Hz，H-10)，1.07(3H，s，H-13)，0.85(3H，s，H-12)。 13C-NMR(DMSO，125MHz)δ：208.1(C-3)，134.9(C-8)， 127.6(C-7)，99.8(C-1′)，85.6(C-5)，80.8(C-6)，77.1(C-5′)， 76.9(C-3′)，76.5(C-11)，73.4(C-2′)，71.7(C-9)，70.2(C-4′)， 61.1(C-6′)，52.9(C-4)，47.7(C-1)，51.8(C-2)，22.2(C-10)， 15.2(C-12)，18.9(C-13)。
26 Herba Cleomis glycosides (glucocaapperin) 1H-NMR (DMSO d6,500MHz) δ: 5.47 (1H, d, J=5.86Hz, H-8), 5.11 (1H, d, J=4.77Hz, H-8), 5.02 (1H, d, J=5.25 Hz, H-8), 4.75 (1H, d, J=9.79Hz, H-8), 4.72 (1H, t, J=5.56Hz, H-8), 3.68 (1H, dd, J=11.16,5.29Hz, H-8), 3.19 (1H, m, H-8), 3.17 (1H, d, J=4.98Hz, H-8), 3.063.17 (2H, m, H-8), 2.23 (3H, s, H). 13C-NMR(DMSO，125MHz)δ： 154.2(C-1)，82.0(C-1′)，81.1(C-5′)，78.1(C-2′)，72.8(C-3′)， 70.0(C-4′)，61.1(C-6′)，18.2(C-2)。
27 Cupreol (β-sitosterol) Slightly
28 β-daucosterol (daucosterol) Slightly
29 Rutin (rutin) Slightly
30 1H-indole-3-carbal-dehyde 1H-NMR (DMSO-d6,500MHz) δ: 7.09～7.15 (2H, overlap, 5,6-H), 7.41 (1H, d, J=7.7Hz, 7-H), 8.05 (1H, d, J=2.9 Hz-H), 8.09 (1H, d, J=7.3Hz, 4-H), 9.94 (1H, s, 10-H), 11.02 (1H, bar, N-H); 13C-NMR (DMSO-d6,125MHz) 8:111.6 (C-7), 118.7 (C-3), 120.8 (C-9), 121.6 (C-4), 123.1 (C-5), 124.1 (C-6), 136.6 (C-2), 136.9 (C-8), 183.9 (C-10).
Another object of the present invention provides the application of described 1,2 and 3 extracts of Capparis spinosa extract in preparation treatment rheumatic arthritis, rheumatoid inflammation, scapulohumeral periarthritis medicine.
Capparis spinosa extract by the inventive method obtains has good analgesia, anti-inflammatory activity through the effect experiment proof.Can be used for treating rheumatic arthritis, rheumatoid arthritis, gout and scapulohumeral periarthritis disease.And prove that through acute toxicity test this extract toxicity is very low.
Extract 1 of the present invention, extract 2 and extract 3 all have antiinflammatory, analgesic activities preferably, and the strong and weak order of anti-inflammatory activity is extract 2＞extract 3＞extract 1; The strong and weak order of central analgesic activities is extract 2 〉=extract 1＞extract 3, and the strong and weak order of periphery analgesic activities is extract 3 〉=extract 1＞extract 2.
Capparis spinosa extract of the present invention can be made tablet, capsule, unguentum (cataplasma), liniment, spray etc. with pharmaceutic adjuvant.
Description of drawings
Fig. 1. the different extract parts of Cortex Capparis Spinosae Radicis fruit improve percentage rate to the mice threshold of pain
Abscissa: percentage rate (%) is improved in the threshold of pain
Ordinate: the time (minute)
The specific embodiment
Embodiment 1: get the Cortex Capparis Spinosae Radicis dry fruit, pulverize, take by weighing 11.5kg, extract 3 times with 95% alcohol heating reflux, each 3h measures 95% ethanol for 7 times for the first time, and the back is 5 times of amount solvents for twice.Merge backflow, 50～80 ℃ of reclaim under reduced pressure temperature, pressure 0.08～0.1MPa) is to equivalent extract (proportion is 1.1～1.4), lyophilization gets the dried cream of crude extract (2.40kg).
With petroleum ether (1～4 times) extraction 2～3 times, (lyophilization gets ligroin extraction (100g) to concentrating under reduced pressure for 30～60 ℃ of temperature, pressure 0.08～0.1MPa) behind crude extract water (1～4 times) dispersing and dissolving.Use ethyl acetate (1～4 times) extraction then, through concentrating under reduced pressure (30～60 ℃ of temperature, pressure 0.08～-0.1MPa) after again after lyophilization, make ethyl acetate extract 2 (60g) and water-soluble active extractive part 3 (1.81kg) respectively.
Embodiment 2: get the Cortex Capparis Spinosae Radicis dry fruit, pulverize, take by weighing 11.5kg, extract 3 times with 85% alcohol heating reflux, each 3h measures 85% ethanol for 7 times for the first time, and the back is 5 times of amount solvents for twice.Merge backflow, 50～80 ℃ of reclaim under reduced pressure temperature, pressure 0.08～0.1MPa) is to equivalent extract (proportion is 1.1～1.4), lyophilization gets the dried cream of crude extract (2.45kg).
With petroleum ether (1～4 times) extraction 2～3 times, (lyophilization gets ligroin extraction (103g) to concentrating under reduced pressure for 30～60 ℃ of temperature, pressure 0.08～0.1MPa) behind crude extract water (1～4 times) dispersing and dissolving.Use ethyl acetate (1～4 times) extraction then, (30～60 ℃ of temperature again after lyophilization, are made ethyl acetate extract (64g) and water-soluble active extractive part (1.9kg) respectively behind the pressure 0.08～0.1MPa) through concentrating under reduced pressure.
Above-mentioned crude extract, ethyl acetate extract and water-soluble active extractive part contain described capparisine A 30 kinds of chemical constituents such as (Capparisine A).
Embodiment 3: get the Cortex Capparis Spinosae Radicis dry fruit, pulverize, take by weighing 11.5kg, extract 3 times with 80% alcohol heating reflux, each 3h measures 80% ethanol for 7 times for the first time, and the back is 5 times of amount solvents for twice.Merge backflow, 50～80 ℃ of reclaim under reduced pressure temperature, pressure 0.08～0.1MPa) is to equivalent extract (proportion is 1.1～1.4), lyophilization gets the dried cream of crude extract (2.5kg).
With petroleum ether (1～4 times) extraction 2～3 times, (lyophilization gets ligroin extraction (106g) to concentrating under reduced pressure for 30～60 ℃ of temperature, pressure 0.08～0.1MPa) behind crude extract water (1～4 times) dispersing and dissolving.Use ethyl acetate (1～4 times) extraction then, (30～60 ℃ of temperature again after lyophilization, are made ethyl acetate extract (66g) and water-soluble active extractive part (1.87kg) respectively behind the pressure 0.08～0.1MPa) through concentrating under reduced pressure.Above-mentioned crude extract, ethyl acetate extract and water-soluble active extractive part contain described capparisine A 30 kinds of chemical constituents such as (Capparisine A).
Embodiment 4: get the Cortex Capparis Spinosae Radicis dry fruit, pulverize, take by weighing 11.5kg, extract 3 times with 60% alcohol heating reflux, each 3h measures 60% ethanol for 7 times for the first time, and the back is 5 times of amount solvents for twice.Merge backflow, (50～80 ℃ of temperature, pressure 0.08～0.1MPa) are to equivalent extract (proportion is 1.1～1.4 to reclaim under reduced pressure), and lyophilization gets the dried cream of crude extract (2.6kg).
Petroleum ether (1～4 times) extraction is 2～3 times behind crude extract water (1～4 times) dispersing and dissolving, and (lyophilization gets ligroin extraction (113g) to concentrating under reduced pressure for 50～80 ℃ of temperature, pressure 0.08～0.1MPa).Use ethyl acetate (1～4 times) extraction then, (30～60 ℃ of temperature again after lyophilization, are made ethyl acetate extract (69g) and water-soluble active extractive part (1.96kg) respectively behind the pressure 0.08～0.1MPa) through concentrating under reduced pressure.Above-mentioned crude extract, ethyl acetate extract and water-soluble active extractive part contain described capparisine A 30 kinds of chemical constituents such as (Capparisine A).
Embodiment 5: get the Cortex Capparis Spinosae Radicis dry fruit, pulverize, take by weighing 11.5kg, the water heating decocts extracts 3 times, each 3h, and 7 times of water gagings for the first time, the back is 5 times of amount solvents for twice.Filter the back and merge decoction liquor, decompression (50～80 ℃ of temperature, pressure 0.08～0.1MPa) is concentrated into equivalent extract (proportion 1.1-1.2), add ethanol and make and contain the alcohol amount and reach more than 65%, leave standstill cold preservation 12h, filter, filtrate decompression (50～80 ℃ of temperature, pressure 0.08～0.1MPa) is concentrated to thick paste (proportion 1.3-1.4), and lyophilization gets the dried cream of crude extract (2.8kg).
With petroleum ether (1～4 times) extraction 2～3 times, (lyophilization gets ligroin extraction (117g) to concentrating under reduced pressure for 30～60 ℃ of temperature, pressure 0.08～0.1MPa) behind crude extract water (1～4 times) dispersing and dissolving.Use ethyl acetate (1～4 times) extraction then, (30～60 ℃ of temperature again after lyophilization, are made ethyl acetate extract (70g) and water-soluble active extractive part (2.20kg) respectively behind the pressure 0.08～0.1MPa) through concentrating under reduced pressure.
Above-mentioned crude extract, ethyl acetate extract and water-soluble active extractive part contain described capparisine A 30 kinds of chemical constituents such as (Capparisine A).
Embodiment 6 ethyl acetate extracts 2 (60g) separate through silica gel (200～300 order) post, with dichloromethane-acetone (100: 0～5: 1), reuse dichloromethane-acetone (20: 1～0: 100) washes successively, and the sample that will get obtains 10 part A 1～10 after merging.With A2, A3, A4 and A5 adopt and mix silica gel on the sample method (200～300 order) post, and petroleum ether-ethyl acetate (5: 1) eluting separates obtaining chemical compound 6,7,8,9 respectively.A6 partly adopts and mixes silica gel on the sample method (200～300 order) post, with petroleum ether-ethyl acetate (5: 1) eluting, through column chromatography and recrystallization repeatedly, obtains chemical compound 10,11,12,13,14,17,18 and 19 again.In addition, A7 partly adopts silica gel column chromatography, with methylene chloride-methanol (15: 1) eluting, obtains chemical compound 22,23 and 25 through column chromatography repeatedly again.A7 partly adopts silica gel column chromatography, with methylene chloride-methanol (10: 1) eluting, obtains chemical compound 17,28,29 through column chromatography repeatedly again.
Water solubility extract 3 (100g) is gone up the C-18 reversed-phase column, with methanol-water (0: 1,1: 3,1.5: 1 and 95: 5) eluting, obtain B1～4 part respectively, wherein B2 is again through silica gel column chromatography, Sephadex LH-20, and the ODS column chromatography separating purification obtains chemical compound 15,14,16,20,21,26.B3 is through silica gel column chromatography, Sephadex LH-20, and the ODS column chromatography separating purification obtains chemical compound 24,1, and 2,3,4,5.
The effect experiment result of the Capparis spinosa extract that embodiment 7 the present invention relates to is as follows:
The preparation of need testing solution: it is an amount of to get among the embodiment 2 listed each extract respectively, water be mixed with the height two dosage medicinal liquid standby, it is respectively as follows that concentration is originally joined by institute: extract 1 high dose (CT-H) (0.131g/ml), extract 1 low dosage (CT-L) is (0.066g/ml); Extract 2 high doses (CE-H) (0.0043g/ml), extract 2 low dosages (CE-L) are (0.002g/ml); Extract 3 high doses (CW-H) (0.122g/ml), extract 3 low dosages (CW-L) are (0.060g/ml); Ligroin extraction high dose (CP-H) (0.0076g/ml), ligroin extraction low dosage (CP-L) is (0.0037g/ml).During dissolving, extract 2 (CE) and ligroin extraction (CP) adopt 1% tween 80 aqueous solution dissolving, and all the other all dissolve with NS.
Take by weighing aspirin (ASP) 1.0g in the volumetric flask of 250ml, the adding distil water dissolving is settled to scale, is made into the solution that concentration is 0.004g/ml, as positive control drug.
Dosage is measured the median lethal dose(LD 50) (LD of Cortex Capparis Spinosae Radicis total ethanol extract 1 through acute toxicity testing 50) be 154.3g/kg (when in crude drug).Total ethanol extract 1 is pressed LD 501/10 and 1/20 administration, its dosage is all calculated in the ratio of shared extractum by all the other each ones.
Antiinflammatory experiment (one): mice caused by dimethylbenzene xylene auricle edema experiment
Get 100 of male mices, body weight 25 ± 2g, weighing is divided into 10 groups behind the labelling at random, is respectively by high and low 2 dosage to be divided into CT-H and CT-L, CE-H and CE-L, CP-H and CP-L, CW-H and CW-L experimental group and blank group (NS) and positive controls (ASP).Each experimental group is pressed CT-H 3.280g/kg, CT-L 1.640g/kg, CE-H 0.108g/kg, CE-L 0.054g/kg, CW-H 0.190g/kg, CW-L 0.095g/kg, CP-H 3.000g/kg, CP-L 1.500g/kg dosage gastric infusion (0.2ml/10g body weight) respectively, positive controls gives ASP 0.080g/kg, and the blank group gives the NS of equal volume.Every d1 time, successive administration 7d.Behind last administration 1h, 30 μ l dimethylbenzene are evenly coated mouse right ear, left ear is not coated with in contrast.After causing scorching 20min, take off cervical vertebra and put to death mice, two auricles about cutting, card punch with diameter 8mm sweeps away left and right sides auricle, on electronic balance, weigh respectively, the difference of left and right sides auricle weight is the swelling degree, calculates and respectively to test inhibitory rate of intumesce (%)=[(cause scorching auricle weigh-do not cause scorching auricle heavy)/do not cause scorching auricle heavily] * 100%.The results are shown in Table 1.
The different extract part xylol of Cortex Capparis Spinosae Radicis cause the influence of mice auricle swelling, and are as shown in table 1.Through the t check analysis as can be seen, positive control drug ASP, ethyl acetate extract (extract 2) and water soluble part (extract 3) are compared with blank NS group, the difference that xylol causes the suppression ratio of mice auricle swelling has statistical significance (p＜0.05 or p＜0.01), and petroleum ether part and ethanol total extract (extract 1) also show certain inhibitory action (p＜0.05).Wherein two groups of inhibition effects with the ASP group of ethyl acetate extract (extract 2) and water soluble part (extract 3) do not have significant difference (p＞0.05).
The different extract part xylol of table 1 Cortex Capparis Spinosae Radicis cause the influence (Mean ± s) of mice auricle swelling
Figure A20081020338200251
Annotate: *Compare (P＜0.05) with the NS group; *Compare (P＜0.01) with the NS group; aCompare (P＞0.05) with the ASP group.
Antiinflammatory experiment (two): the experiment of mouse peritoneal capillary permeability
Get 100 of mices, body weight 20 ± 2g, male and female half and half are divided into 10 groups at random behind the labelling of weighing, 10 every group.Experiment grouping and dosage are identical with the experiment of mice caused by dimethylbenzene xylene auricle edema with method.Behind last administration 1h, the blue 0.1ml/10g of tail vein injection 0.5% ivens, lumbar injection 0.6% acetum 0.3ml/ only immediately, behind the 20min, take off cervical vertebra and put to death mice, cut off the abdominal cavity, with 5ml NS flushing abdominal cavity for several times, collect cleaning mixture in the 5ml measuring bottle, fixed with NS to scale, the centrifugal 5min of 3000r/min, with NS is blank, with the trap (OD value) of 752 type spectrophotometers in 608nm wavelength place mensuration supernatant, the record result is calculated as follows the capillary permeability suppression ratio.Capillary permeability suppression ratio (%)=[(blank group OD value-experimental group OD value)/blank group OD value] * 100% the results are shown in Table 2.
The different extract parts of Cortex Capparis Spinosae Radicis are to the influence of mouse peritoneal capillary permeability, and are as shown in table 2.Through the t check analysis as seen, the ethyl acetate extract of Cortex Capparis Spinosae Radicis fruit ethanol extraction (extract 2) high dose group and positive control ASP group relatively has significant difference (P＜0.05) to the inhibitory action and the blank NS group of mouse peritoneal capillary permeability.And ethyl acetate extract (extract 2) high dose group and positive control drug ASP group be there was no significant difference (p＞0.05) relatively.
The different extract parts of table 2 Cortex Capparis Spinosae Radicis are to the influence of mice capillary permeability (Mean ± s)
Annotate: *Compare (P＜0.05) with the NS group; aCompare (P＞0.05) with the ASP group.
Analgesic experiment (one): hot plate method experiment
It is some to get female mice, only pursues earlier before formal experiment and screens with YLS-6B intelligence hot-plate instrument (temperature transfers to 55 ± 0.5 ℃).Get 1 of mice during screening at every turn, record mice vola contact hot plate is to licking metapedes required time (s, the hot plate response latency), rejects the response latency earlier greater than 30s's or less than bradykinesia or the mice hypersensitive of 5s as threshold of pain index (measure altogether 2 times, obtain the meansigma methods of measuring for 2 times).The qualified animal (filtering out 100 of qualified animals by 150 mices) of screening is divided into 10 groups at random, 10 every group, body weight 20 ± 2g, the back labelling of weighing.Experiment grouping and dosage are identical with the experiment of mice caused by dimethylbenzene xylene auricle edema with method.Respectively at after the last administration 30,60,90,120min measures pain threshold respectively by above-mentioned basic pain threshold algoscopy, surpasses 60s as the threshold of pain, promptly stops test and by 60s, in order to avoid scald foot.And be calculated as follows its threshold of pain and improve percentage rate.Percentage rate (%)=[average pain threshold before (the preceding average pain threshold of average pain threshold-administration after the administration)/administration] * 100% is improved in the threshold of pain.The results are shown in Table 3 and Fig. 1.
The different extract parts of Cortex Capparis Spinosae Radicis are to the influence of the mice hot plate method analgesic experiment threshold of pain, as table 3 and shown in Figure 1.Improving percentage rate with the threshold of pain had analgesia to render a service greater than 50% o'clock, the high and low dose group of ethanol total extract (extract 1), ethyl acetate extract (extract 2) and petroleum ether part all can obviously improve the threshold of pain (percentage rate＞50% is improved in the threshold of pain) of mice hot plate method experiment, and prolongation along with action time, analgesic activity has enhanced trend, shows analgesic effect preferably.And water soluble part (extract 3) though the threshold of pain improve percentage rate also greater than 50%, act on by contrast than a little less than other position.
Table 3 Cortex Capparis Spinosae Radicis different parts is to the influence of the different time sections mice threshold of pain and threshold of pain raising rate (Mean ± s)
Figure A20081020338200261
Annotate: bracket inner digital is that percentage rate (%) is improved in the threshold of pain
Analgesic experiment (two): acetic acid twisting method experiment
Get 100 of mices, body weight 18～22g, male and female half and half are divided into 10 groups at random behind the labelling of weighing, 10 every group.Experiment grouping and dosage are identical with the experiment of mice caused by dimethylbenzene xylene auricle edema with method.Respectively at 1h after the last administration, lumbar injection 0.6% acetum 0.1ml/10g (acetum face use preceding preparation).Observe and write down the number of times that occurs writhing response (abdominal part shrinks indent, stretches hind leg, and buttocks is raised, crawling) in the 15min behind the 5min, be calculated as follows the writhing response suppression ratio.Writhing response suppression ratio (%)=[(matched group is on average turned round body number of times-administration group and on average turned round the body number of times)/matched group is on average turned round the body number of times] * 100%.The results are shown in Table 4.
The influence of the analgesic experiment of the different extract part Dichlorodiphenyl Acetate of Cortex Capparis Spinosae Radicis writhing response, as shown in table 4.As can be seen from Table 4, ethanol total extract (extract 1), petroleum ether part, ethyl acetate extract (extract 2) and water soluble part (extract 3) all can obviously reduce acetic acid and inject visceral layer that intraperitoneal causes and parietal peritoneum than the inflammatory pain of large tracts of land long period, and wherein the analgesic effect of the high dose group of the high dose group of ethanol total extract (extract 1) and water soluble part is best.
Table 4 Cortex Capparis Spinosae Radicis different parts Dichlorodiphenyl Acetate causes the influence (Mean ± s) of mouse writhing reaction
Annotate: *Compare (P＜0.05) with the NS group

Claims (5)

1, a kind of Capparis spinosa extract is characterized in that this Capparis spinosa extract comprises extract 1,2 and 3; Described extract 1 contains following 30 kinds of chemical compounds: chemical compound 1: capparisine A, chemical compound 2: cappariside A, chemical compound 3: capparisine B, chemical compound 4: capparisine C, chemical compound 5: capparisine D, chemical compound 6: P-hydroxybenzoic acid, chemical compound 7: protocatechuic acid, chemical compound 8: vanillic acid, chemical compound 9: former youngster's aldehyde, chemical compound 10: syringic acid, chemical compound 11:3, the 4-resorcylic acid, chemical compound 12: fumaroyl, chemical compound 13: ethanedioic acid, chemical compound 14:5-Hydroxymethylfurfural, chemical compound 15:5-methylol furancarboxylic acid, chemical compound 16:2-furancarboxylic acid, chemical compound 17: dihydro-4 hydroxyls-5-methylol-2 (3H) furanone, chemical compound 18:7-hydroxy-2-oxoindolin-3-ylacetic acid, chemical compound 19: uracil, chemical compound 20:L-meso inositol, chemical compound 21: uridnine, chemical compound 22: kaempferol rutin, chemical compound 23: β-daucosterol-6 '-stearate, chemical compound 24:corchoionoside C, chemical compound 25:spionoside B, chemical compound 26: Herba Cleomis glycosides, chemical compound 27: cupreol, chemical compound 28: β-daucosterol, chemical compound 29: rutin, chemical compound 30: indole-3-formaldehyde;
Their structural formula is as follows:
Figure A2008102033820003C1
Figure A2008102033820004C1
The characteristic wave spectrum data of above-mentioned 30 kinds of chemical compounds:
Compile
The title spectral data
Number
1 capparisine A 1H-NMR (DMSO-d 6, 500MHz) δ (ppm): 11.34bar (COOH),
9.34(1H，s，CHO)，7.13(1H，d，J＝3.8Hz，H-8)，6.29(1H，
d，J＝3.9Hz，H-9)，5.64(1H，m，H-5)，5.40m(1H，s，
NH)，3.08(1H，dd，J＝9.2Hz，17.0Hz，H-4a)，2.63(1H，
dd，J＝6.6Hz，17.0Hz，H-4b)； 13C-NMR(CD 3OD，125MHz)
δ(ppm)：179.0(C-11)，175.2(C-12)，175.1(C-3)，125.8(C-8)，
144.9(C-10)，131.3(C-7)，109.7(C-9)，54.8(C-1)，54.7(C-5)，
37.3(C-4)；
2 Cortex Capparis Spinosae Radicis acid 1H-NMR (DMSO, 500MHz) δ (ppm): 7.93 (1H, s, H-2),
2.31(3H，s，CH 3)； 13C-NMR(CD 3OD，125MHz)δ(ppm)：
170.6(COOH)，152.2(C-4)，146.1(C-3)，143.2(C-5)，
140.7(C-2)，14.8(CH 3)；
3 capparisine B 1H-NMR (DMSO, 500MHz) δ (ppm): 9.54 (1H, s, CHO),
6.98(1H，d，J＝4.01Hz)，6.21(1H，d，J＝3.78Hz)，5.84(1H，
q，J＝7.24Hz)，5.48(1H，d，J＝14.13Hz)，5.39(1H，d，
J＝14.93Hz)，1.72(3H，d，J＝7.27Hz CH3)； 13C-NMR
(CD3OD，125MHz)δ(ppm)：179.7(C-11)，168.1(C-3)，
130.8(C-6)，120.3(C-9)，124.0(C-7)，106.5(C-6)，63.3(C-1)，
53.8(C-4)，19.1(C-10)；
4 capparisine C 1H-NMR (DMSO, 500MHz) δ (ppm): 9.46 (1H, s, CHO),
6.93(1H，d，J＝3.69Hz，H-3)，6.03(1H，d，J＝3.52Hz，
H-4)，4.96(1H，d，J＝15.35Hz，H-7a)，4.76(1H，d，J＝15.29
Hz，H-7b)，4.66(1H，d，J＝14.01Hz，H-6a)，4.34(1H，d，
J＝13.58Hz，H-6b)，4.34(1H，m，H-5′)，4.25(1H，m，H-4′)，
3.77(1H，dd，J＝2.49，12.29Hz，H-3′a)，3.69(1H，dd，J
＝3.64.49，11.87Hz，H-3′b)，2.27(1H，m，H-6′)； 13C-NMR
(CD 3OD，125MHz)δ(ppm)：178.9(C-8)，134.6(C-5)，
131.2(C-2)，124.2(C-4)，105.0(C-3)，104.1(C-1′)，89.7(C-1′)，
72.9(C-5′)，62.9(C-3′)，58.0(C-7)，50.3(C-6)，44.9(C-6′)；
5 capparisine D 1H-NMR (DMSO, 500MHz) δ (ppm): 9.45 (1H, s, CHO),
6.92(1H，d，J＝3.80Hz，H-7′)，6.01(1H，d，J＝3.46Hz，
H-8′)，4.82(1H，d，J＝15.18Hz，H-1′a)，4.74(1H，d，J
＝15.67Hz，H-1′b)，4.70(2H，d，J＝14.37Hz，H-4′a)，4.02
(1H，d，J＝13.82Hz，H-4′b)，4.17(1H，m，H-4)，3.88(1H，
s，H-5)，3.89(1H，d，J＝12.07Hz，H-6a)，3.81(1H，d，J＝12.07
Hz，H-6b)，2.04(1H，dd，J＝5.32，12.82Hz，H-3a)，1.91
(1H，t，J＝12.43Hz，H-3b)；13C-NMR(CD 3OD，125MHz)
δ(ppm)：178.8(C-10′)，134.1(C-9′)，131.2(C-6′)，124.0(C-7′)，
104.8(C-8′)，95.4(C-2)，67.4(C-5)，65.1(C-4)，64.5(C-6)，
57.8(C-1′)，52.2(C-4′)，35.8(C-3)；
6 P-hydroxybenzoic acid 1H-NMR (CD 3OD, 500MHz) δ (ppm): 7.78 (2H, d, J=8.8
Hz, H-3,5), 6.72 (2H, d, J=8.8Hz, H-2,6) are ortho position phenol
The hydroxyl hydrogen signal; 13C-NMR (CD 3OD, 125MHz) δ (ppm): 170.4
(C-7)，163.6(C-4)，133.3(C-2，C-6)，123.0(C-1)，116.3(C-3，
C-5)；
7 protocatechuic acid 1H-NMR (CD 3OD, 500MHz) δ (ppm): 7.31 (1H, d, J=1.7
Hz，H-2)，7.2(1H，dd，J＝8.1，1.7Hz，H-6)，6.9(1H，d，
J＝8.1Hz，H-5)； 13C-NMR(CD 3OD，125MHz)δ(ppm)：
170.7(COOH)，151.8(C-4)，46.3(C-3)，124.2(C-6)，
123.5(C-1)，118.1(C-2)，116.1(C-5)；
8 vanillic acids 1H-NMR (CD 3COCD 3, 500MHz) δ (ppm): 12.44 (1H, br.s,
COOH)，9.81(1H，br.s，OH)，7.46(1H，dd，J＝8.2，1.7
Hz，H-6)，7.43(1H，d，J＝1.7Hz，H-2)，6.77(1H，d，J＝8.2
Hz，H-5)，3.79(3H，s，OCH 3)； 13C-NMR(CD 3COCD 3，
125MHz)δ(ppm)：167.5(C-1)，152.1(C-4)，148.1(C-5)，
124.9(C-7)，122.9(C-2)，115.5(C-3)，113.5(C-6)，56.4
(OCH 3)；
9 protocatechualdehyde 1H-NMR (CD 3COCD 3, 500M Hz) and δ (ppm): 9.67 (s, 1H),
8.64(2H，br.s，OH)，7.24(1H，d，J＝1.84Hz，H-2)，7.22
(1H，dd，J＝8.03，1.86Hz，H-6)，6.87(1H，d，J＝8.01
Hz，H-5)；
10 syringic acids 1H-NMR (500MHz, CD 3OD) δ (ppm): 7.20 (2H, s, H-2),
3.76(6H，s，OCH 3)； 13C-NMR(CD 3OD，125MHz)δ(ppm)：
167.5(COOH)，148.4(C-3，5)，141.6(C-4)，121.5(C-1)，
108.2(C-2，6)，56.7(OCH 3)；
11 3, the 4-resorcylic acid 1H-NMR (MeOD, 500MHz) δ (ppm): 7.37 (1H, d, J=2.0
Ethyl ester HzH-2), 7.31 (1H, dd, J=2.0,8.3Hz, H-6), 6.76 (1H, d,
J＝8.3Hz，H-5)，4.13(2H，q，OCH 2)，1.19(3H，t，-CH 3)；
13C-NMR(CD 3OD，125MHz)δ(ppm)：166.6(C＝O)，150.7
(C-4)，145.6(C-3)，123.3(C-1，6)，122.9(C-2，1)，117.2
(C-5)，115.7(C-2)，60.8(OCH 2)，14.6(CH 3)；
12 fumaric acid 1H-NMR (CD 3OD, 500MHz) δ (ppm): 6.81 (1H, d, J=15.8
Hz，H-2)，6.48(1H，d，J＝15.8Hz，H-3)； 13C-NMR(CD 3OD，
125MHz)δ(ppm)：134.8(C-2，C-3)，166.1(C-1，C-4)；
13 succinic acid 1H-NMR (CD 3OD, 500MHz) δ (ppm): 2.5 (4H, d, J=15.8Hz,
H-2，3)； 13C-NMR(CD 3OD，125MHz)δ(ppm)：176.5(C-1，
C-4)，30.1(C-2，C-3)；
14 5 hydroxymethyl furfurals 1H-NMR (MeOD, 400MHz) δ (ppm): 11.16 (1H, s, COOH),
7.78(1H，d，J＝0.82Hz，H-3)，7.22(1H，dd，J＝3.32，0.36
Hz，H-5)，6.62(1H，dd，J＝3.33，1.73Hz，H-4)； 13C-NMR
(MeOD，125MHz)δ(ppm)：159.4(C-1′)，147.6(C-5)，145.9
(C-2)，118.6(C-3)，112.7(C-4)；
15 5-methylol furancarboxylic acids 1H-NMR (CD 3OD, 500M Hz) δ (ppm): 7.06 (1H, d, J=3.42
Hz，H-3)，6.36(1H，d，J＝3.43Hz，H-4)，4.47(3H，s，H 2)；
13C-NMR(CD 3OD，125MHz)δ(ppm)：162.08(C-2′)，160.99
(C-2)，45.99(C-5)，120.28(C-3)，110.51(C-4)，57.8(C-5′)；
16 2-furancarboxylic acids 1H-NMR (MeOD, 400MHz) δ: 11.16 (1H, s, COOH), 7.78 (1H,
d，J＝0.82Hz，H-5)，7.22(1H，dd，J＝3.32，0.36Hz，H-3)，
6.62(1H，t，J＝3.33，1.73Hz，H-4)； 13C-NMR(MeOD，
125MHz)δ：159.41(s，C-1′)，147.61(s，C-5)，145.96(s，C-2)，
118.62(s，C-4)，112.71(s，C-3)；
17 dihydros-4 hydroxyls-5-hydroxyl 1H-NMR (MeOD, 500MHz) δ: 4.42 (1H, m, 5-H); 4.36 (1H,
Methyl-2 (3H) furanone t, J=2.2Hz, J=3.5Hz, 4-H); 3.76 (1H, dd, J=12.4Hz, J=3.3Hz
6-H)；3.68(1H，dd，J＝12.5Hz，J＝3.6Hz，6-H)；2.91(1H，
dd，J＝18Hz，J＝6.8Hz，3-H)；2.37(1H，dd，J＝17.8Hz，
J＝2.6Hz，3-H)； 13C-NMR(MeOD，125MHz)δ：178.9(C-2)，
90.5(C-5)，69.9(C-4)，62.8(C-6)，39.4(C-3)；
18 7-hydroxy-2-oxoin 1H-NMR(MeOD，500MHz)δ：6.76(1H，t，J＝7.67，H-5)；
dolin-3-ylacetic 6.72(1H，dd，J＝1.1，7.52Hz，H-4)；6.66(1H，dd，J＝7.69，
acid 1.5Hz，H-6)；3.81(1H，dd，J＝3.45Hz，6.41Hz，H-3)；
2.75(1H，dd，J＝16.44，J＝3.46Hz，H-11)；2.66(1H，dd，
J＝16.44，J＝6.57Hz，H-11)； 13C-NMR(MeOD，125MHz)δ：
175.9(C-11)，172.0(C-2)，145.8(C-7)，126.8(C-8)，124.6(C-5)，
123.5(C-9)，121.0(C-4)，115.8(C-6)，44.0(C-3)，34.4(C-10)；
19 uracil 1H-NMR (DMSO d 6, 500MHz) δ: 13.11 (1H, s), 12.43 (1H,
s)，7.59(1H，d，J＝7.56Hz)，5.88(1H，d，J＝7.57Hz)。
13C-NMR(DMSO-d 6，125MHz)δ：165.9(C-4)，153.3(C-2)，
101.4(C-5)，142.2(C-6)。 1Proton signal δ on the H-NMR H13.11 (1H,
S), 12.43 (1H s) is the signal of active proton, δ H7.59 (1H, d,
J=7.5H7), 5.40 (1H, d J=7.5Hz) are the olefinic proton signal. 13C-NMR
Spectrum shows 4 carbon signals: 165.9,153.3,142.2,101.4 belong to respectively
Carbon signal for unsaturated amides, urea groups and two keys;
20 meso inositols 13C-NMR (DMSO, 400MHz) δ C: 74.3,72.4,72.2,71.1,
All be to connect oxygen carbon, δ C: 72.4,71.1 two carbon signal peaks are higher, and they are described
Be respectively two carbon signals, chemical compound should be hexa-atomic cyclic alcohol.
1H-NMR(DMSOO，400MHz)：δ4.52(1H，d，J＝3.72Hz)
δ4.46(1H，d，J＝4.19Hz)，δ4.44(2H，d，J＝3.07Hz)，δ4.32(2H，
d，J＝5.43Hz)，δ3.70(1H，d，J＝2.68Hz)，δ3.37(1H，dd，
J＝2.68.9.34Hz)，δ3.11(2H，m)，2.90(1H，td，J＝9.1，4.07
Hz), there is a hydrogen to be in the e key, other five hydrogen from their coupling constant
All be in a key;
21 uridnine 1H-NMR (DMSO d 6, 400MHz) δ: 7.98 (1H, d, J=8.1Hz,
H-6), 5.89 (1H, d, J=4.6Hz, H-1 ') are sugared terminal hydrogen signal, because of
Coupling constant is 4.6, is indicated as the α configuration, 5.69 (1H, d, J=8.1, H=8.1Hz,
H-5), 3.7～4.2, be the hydrogen signal on the sugar. 13C-NMR(DMSO-d 6，
400MHz)δ：166.5(C-4)，152.8(C-2)，143.0(C-6)，91.0(C-5)，
Be the carbon signal of uracil, 102.9 is sugared end group carbon signal, other δ 86.6,
76.0 71.6,62.6 are the carbon signal of sugar, are pentose;
22 kaempferol 3-O-rutins 1H-NMR (DMSO-d, 500MHz) δ: 12.56 (5OH), 10.80 (1H,
br s，OH)，10.09(1H，br s，OH)，7.98(2H，d，J＝8.6Hz，
IH-2′，6′)，6.87(2H，d，J＝8.6Hz，H-3′，5′)，6.41(1H，s，
H-8)，6.20(1H，s，H-6)，5.31(1H，d，J＝7.3Hz，H-1″，
ofglucose)，4.38(1H，brs，H-rhamnose)，0.99(3H，d，J＝6.1Hz，
rha-CH 3)； 13C-NMR(DMSO-d，125MHz)δ：177.3(C-4)，
164.1(C-7)，161.2(C-5)，159.8(C-4′)，156.8(C-9)，156.4(C-2)，
133.1(C-3)，130.8(C-2′，6′)，120.9(C-1′)，115.0(C-3′，5′)，
103.9(C-10)，101.3(C-1″)，100.7(C-1″′)，98.7(C-6)，93.7(C-8)，
76.3(C-3″)，75.7(C-5″)，74.1(C-2″)，71.8(C-4″′)，70.6(C-3″′)，
70.3(C-4″)，69.9(C-2″′)，68.2(C-5″′)，66.8(C-6″)，17.7(C-6″′)；
23 β-daucosterol-6 '-hard 1H-NMR (CDCl3,500MHz) δ: 0.65 (3H, s, C18-H), 0.80-0.98
Fat acid ester (m, CH 3), 1.25 (bra, CH 2), 1.47-2.00 (CH 2And CH), 2.34 (2H,
t，J＝7.5Hz，CH2COO)，3.36(1H，m，C3-H)，3.51-4.37(m，
Hydrogen on the sugar), 5.34 (1H, m, C6-H). 13C-NMR(CDCl3，125MHz)
δ：174.2，140.4，122.1，101.3，79.8，76.2，73.8，73.4，
70.5，63.6，56.8，56.2，50.2，45.9，42.4，39.8，38.9，37.3，
36.7，36.2，34.3，33.9，31.9，31.9，29.7-29.8，29.5，29.34，
29.34，29.3，29.2，28.3，26.3，25.0，24.32，23.1，22.7，
21.1，19.8，19.05，18.80，14.10，11.98，11.87；
24 6，9-Dihydroxy-4， 1H-NMR(MeOD-d 6，500MHz)δ：5.78(1H，s，H-5)，5.70(2H，
7-megastigmadien- m，H-6，7)，4.22(1H，dq，J＝6.4，4.4Hz，H-9)，2.41(1H，
3-onel d，J＝16.8Hz，H-a)，2.06(1H，d，J＝16.9Hz，H-2β)，1.82
(1H，d，J＝1.2Hz，H-13)，1.14(3H，d，J＝6.5Hz，H-10)，
0.94(3H，s，H-11)，0.91(3H，s，H-12)。 13C-NMRδ：201.5(C-3)，
167.7(C-5)，137.3(C-7)，130.4(C-7)，130.3(C-8)，127.4(C-4)，
80.3(C-6)，69.0(C-9)，51.1(C-2)，42.7(C-1)，24.8(C-12)，
24.1(C-11)，23.8(C-4)，19.8(C-13)；
25 spionoside B 1H-NMR(DMSO-d6，500MHz)δ：6.26(1H，d，J＝15.26Hz，
H-7)，5.94(1H，dd，J＝15.25，6.11Hz，H-8)，4.75(OH)，
4.48(1H，dq，J＝6.27，6.36Hz，H-9)，4.14(1H，d，J＝7.64
Hz，H-1′)，3.75(2H，dd，J＝7.32，2.49Hz，H-11a)，3.49(1H，
d，J＝7.39Hz，H-11b)，3.63(1H，m，H-6′a)，3.38(1H，m，
H-6′b)，2.9～3.1(4H，m，H-2′，3′，4′，5′)，2.27(d，J＝17.47
Hz，H-4a)，2.71(d，J＝17.2Hz，H-4b)，2.67(dd，J＝16.78，
1.54Hz，H-2a)，2.22(d，J＝17.59Hz，H-2b)，1.22(d，J＝6.49
Hz，H-10)，1.07(3H，s，H-13)，0.85(3H，s，H-12)。
13C-NMR(DMSO，125MHz)δ：208.1(C-3)，134.9(C-8)，
127.6(C-7)，99.8(C-1′)，85.6(C-5)，80.8(C-6)，77.1(C-5′)，
76.9(C-3′)，76.5(C-11)，73.4(C-2′)，71.7(C-9)，70.2(C-4′)，
61.1(C-6′)，52.9(C-4)，47.7(C-1)，51.8(C-2)，22.2(C-10)，
15.2(C-12)，18.9(C-13)；
26 Herba Cleomis glycosides 1H-NMR (DMSO d6,500MHz) δ: 5.47 (1H, d, J=5.86Hz,
H-8)，5.11(1H，d，J＝4.77Hz，H-8)，5.02(1H，d，J＝5.25
Hz，H-8)，4.75(1H，d，J＝9.79Hz，H-8)，4.72(1H，t，
J＝5.56Hz，H-8)，3.68(1H，dd，J＝11.16，5.29Hz，H-8)，
3.19(1H，m，H-8)，3.17(1H，d，J＝4.98Hz，H-8)，3.063.17(2H，
m，H-8)，2.23(3H，s，H)。 13C-NMR(DMSO，125MHz)δ：
154.2(C-1)，82.0(C-1′)，81.1(C-5′)，78.1(C-2′)，72.8(C-3′)，
70.0(C-4′)，61.1(C-6′)，18.2(C-2)；
27 cupreols slightly
28 β-daucosterol slightly
29 rutins slightly
30 1H-indole-3-carbal- 1H-NMR(DMSO-d6，500MHz)δ：7.09～7.15(2H，overlap，
dehyde 5，6-H)，7.41(1H，d，J＝7.7Hz，7-H)，8.05(1H，d，J＝2.9
Hz-H)，8.09(1H，d，J＝7.3Hz，4-H)，9.94(1H，s，10-H)，
11.02(1H，bar，N-H)； 13C-NMR(DMSO-d6，125MHz)8：
111.6(C-7)，118.7(C-3)，120.8(C-9)，121.6(C-4)，123.1(C-5)，
124.1(C-6)，136.6(C-2)，136.9(C-8)，183.9(C-10)。
2, Capparis spinosa extract according to claim 1 is characterized in that described extract 2 comprises following chemical components: chemical compound 6,7,8,9,10,11,12,13,17,18,19,22,23,25,27,28,29 and 30; Extract 3 comprises following chemical components: chemical compound 1,2,3,4,5,14,15,16,20,21,24 and 26.
3, a kind of preparation method of Capparis spinosa extract according to claim 1 is characterized in that this method comprises the following steps:
(1) with pulverizing medicinal materials, boil 2～3 times with 5～10 times of W/W decoctings of medical material, or extract 2～3 times with 50～95% alcohol heating reflux of 5～8 times of amounts of medical material W/W, merge each time extracting solution;
(2) concentrated solution of decocting liquid adds ethanol and makes that to contain the alcohol amount in the solution be 60～80%, precipitated impurities, precipitate with ethanol is 2 times altogether, removes precipitation, 50～80 ℃ of supernatant concentrating under reduced pressure temperature, pressure 0.08～0.1MPa, reclaim behind the ethanol concentrated solution density 1.03-1.1; Or with 50～80 ℃ of the ethanol extract concentrating under reduced pressure temperature of step (1), pressure 0.08～0.1MPa, reclaim behind the ethanol concentrated solution density 1.03-1.1;
(3) concentrated solution gets crude extract 1 through 50～80 ℃ of drying under reduced pressure temperature after pressure 0.08～0.1MPa or the lyophilization;
(4) after 1～3 times of amount of crude extract 1 usefulness crude extract W/W aqueous dispersion dissolving, take off ester 2～3 times with 1～1.5 times of amount V/V petroleum ether, with 1～1.5 times of amount V/V ethyl acetate extraction, aqueous solution after taking off ester 2～3 times, get ethyl acetate part and water-soluble portion, this two parts liquid is respectively through 30～50 ℃ of concentrating under reduced pressure temperature, behind pressure 0.08～0.1MPa, after decompression, vacuum or lyophilization, make ethyl acetate extract 2 and water soluble part extract 3 again.
4, a kind of Capparis spinosa extract as claimed in claim 1 or 2 is in preparation treatment rheumatic arthritis, application in rheumatoid inflammation or the scapulohumeral periarthritis medicine, it is characterized in that described extract comprises following 30 kinds of chemical compounds: chemical compound 1: capparisine A, chemical compound 2: cappariside A, chemical compound 3: capparisine B, chemical compound 4: capparisine C, chemical compound 5: capparisine D, chemical compound 6: P-hydroxybenzoic acid, chemical compound 7: protocatechuic acid, chemical compound 8: vanillic acid, chemical compound 9: former youngster's aldehyde, chemical compound 10: syringic acid, chemical compound 11:3, the 4-resorcylic acid, chemical compound 12: fumaroyl, chemical compound 13: ethanedioic acid, chemical compound 14:5-Hydroxymethylfurfural, chemical compound 15:5-methylol furancarboxylic acid, chemical compound 16:2-furancarboxylic acid, chemical compound 17: dihydro-4 hydroxyls-5-methylol-2 (3H) furanone, chemical compound 18:7-hydroxy-2-oxoindolin-3-ylacetic acid, chemical compound 19: uracil, chemical compound 20:L-meso inositol, chemical compound 21: uridnine, chemical compound 22: kaempferol rutin, chemical compound 23: β-daucosterol-6 '-stearate, chemical compound 24:corchoionoside C, chemical compound 25:spionoside B, chemical compound 26: Herba Cleomis glycosides, chemical compound 27: cupreol, chemical compound 28: β-daucosterol, chemical compound 29: rutin, chemical compound 30: indole-3-formaldehyde.
5,, it is characterized in that described medicine is tablet, capsule, unguentum, cataplasma, liniment or the spray that Capparis spinosa extract and pharmaceutic adjuvant are made according to the application of claim 4.
CNA2008102033822A 2008-11-26 2008-11-26 Capparis spinosa extract as well as preparation method and application thereof Pending CN101406497A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA2008102033822A CN101406497A (en) 2008-11-26 2008-11-26 Capparis spinosa extract as well as preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2008102033822A CN101406497A (en) 2008-11-26 2008-11-26 Capparis spinosa extract as well as preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN101406497A true CN101406497A (en) 2009-04-15

Family

ID=40569842

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2008102033822A Pending CN101406497A (en) 2008-11-26 2008-11-26 Capparis spinosa extract as well as preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN101406497A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102423323A (en) * 2011-12-12 2012-04-25 中国科学院新疆理化技术研究所 Compound medicine for treating rheumatism and preparation method thereof
ITMO20130241A1 (en) * 2013-08-22 2015-02-23 Paolo Puccetti USE OF INDOLO-3-ALDEHYDE FOR THE TREATMENT OF IMMUNE DISREATIVE DISEASES
CN104628803A (en) * 2015-02-06 2015-05-20 大连理工大学 Total synthesis method for rape pollen alkali A and caper alkali B and analogues thereof
CN105859745A (en) * 2015-01-20 2016-08-17 复旦大学 Selective synthetic method of natural products Xylapyrroside A
CN105884845A (en) * 2015-01-26 2016-08-24 复旦大学 Pyrrole and morpholine spirocyclic alkaloid compound and preparation method and application thereof
CN108125997A (en) * 2018-02-12 2018-06-08 中南民族大学 Caper ethyl acetate extract application in preparation of anti-tumor drugs
CN109303790A (en) * 2018-12-04 2019-02-05 上海中医药大学附属曙光医院 The medical usage of caper or Capparis spinosa extract
CN109381497A (en) * 2017-08-08 2019-02-26 上海医药工业研究院 Capparis spinosa extract, preparation method and application
CN112251912A (en) * 2020-10-19 2021-01-22 新疆大学 Capparis spinosa drug-loaded nanofiber membrane as well as preparation method and application thereof
CN114099558A (en) * 2021-12-06 2022-03-01 新疆农业大学 Preparation method and application of caper fruit extract
CN114949017A (en) * 2022-06-27 2022-08-30 新疆前进荣耀投资有限公司 Capparis spinosa alcohol extract, preparation method and application thereof in preparing antioxidant product and/or blood fat reducing product

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102423323A (en) * 2011-12-12 2012-04-25 中国科学院新疆理化技术研究所 Compound medicine for treating rheumatism and preparation method thereof
ITMO20130241A1 (en) * 2013-08-22 2015-02-23 Paolo Puccetti USE OF INDOLO-3-ALDEHYDE FOR THE TREATMENT OF IMMUNE DISREATIVE DISEASES
WO2015025259A1 (en) * 2013-08-22 2015-02-26 Universita' Degli Studi Di Perugia Indole-3-aldehyde for treating dysreactive immune disorders
US10751322B2 (en) 2013-08-22 2020-08-25 Universita′ degli Studi di Perugia Indole-3-aldehyde for treating dysreactive immune disorders
CN105859745A (en) * 2015-01-20 2016-08-17 复旦大学 Selective synthetic method of natural products Xylapyrroside A
CN105884845A (en) * 2015-01-26 2016-08-24 复旦大学 Pyrrole and morpholine spirocyclic alkaloid compound and preparation method and application thereof
CN104628803B (en) * 2015-02-06 2017-08-22 大连理工大学 A kind of rape pollen alkali A and caper alkali D and the like total synthesis method
CN104628803A (en) * 2015-02-06 2015-05-20 大连理工大学 Total synthesis method for rape pollen alkali A and caper alkali B and analogues thereof
CN109381497A (en) * 2017-08-08 2019-02-26 上海医药工业研究院 Capparis spinosa extract, preparation method and application
CN108125997A (en) * 2018-02-12 2018-06-08 中南民族大学 Caper ethyl acetate extract application in preparation of anti-tumor drugs
CN109303790A (en) * 2018-12-04 2019-02-05 上海中医药大学附属曙光医院 The medical usage of caper or Capparis spinosa extract
CN109303790B (en) * 2018-12-04 2021-07-20 上海中医药大学附属曙光医院 Medical application of caper or caper extract
CN112251912A (en) * 2020-10-19 2021-01-22 新疆大学 Capparis spinosa drug-loaded nanofiber membrane as well as preparation method and application thereof
CN114099558A (en) * 2021-12-06 2022-03-01 新疆农业大学 Preparation method and application of caper fruit extract
CN114949017A (en) * 2022-06-27 2022-08-30 新疆前进荣耀投资有限公司 Capparis spinosa alcohol extract, preparation method and application thereof in preparing antioxidant product and/or blood fat reducing product

Similar Documents

Publication Publication Date Title
CN101406497A (en) Capparis spinosa extract as well as preparation method and application thereof
CN101721400A (en) Action of ferulic acid on enhancing drug effect of some medicaments and purpose thereof
CN102178741B (en) Guava leaf extract with function of reducing blood sugar as well as preparation method and application thereof
CN101585825B (en) Method for preparing amentoflavone
CN107260892A (en) A kind of preparation method of the camellia petal extract with hypolipemic function
CN1569869B (en) Chinese chestnut flower flavone compounds
CN102898322B (en) Compound and preparation method and application thereof
CN102875615A (en) Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf
CN102048874B (en) General flavone extractive of immature bitter orange or bitter orange extracted through water decoction and use of general flavone extractive
CN103626812A (en) Novel parishin compound in gastrodia elata and application of compound
CN103110680A (en) Preparation method of total phenolic acid of erigeron breviscapus
CN102093380B (en) Cyclic icaritin aglycon as well as preparation method and application of cyclic icaritin aglycon
CN105726656A (en) Composition for treating gynecological inflammation, preparing method thereof and suppository for treating gynecological inflammation
CN102406735A (en) Immature bitter orange or bitter orange total flavonoid extract decocted and extracted by water and its purpose
CN103127235B (en) Preparation method of medicine having liver protection and liver fibrosis effects
CN102391335B (en) Isopentene flavonol glycoside derivative and preparation method and application thereof
CN102988342B (en) Application of cyclo-icaritin aglycone in preparation of anti-inflammatory and antimicrobial medicaments
CN104288169B (en) A kind of flavonoid glycoside compound and its production and use
CN103923156B (en) There is saponin compound and the application thereof of hepatoprotective effect
CN106008216A (en) Pharmaceutical composition of didanosine and application of pharmaceutical composition in biological medicines
CN109810153B (en) Preparation method and analgesic application of aromatic substituted glucose compound and pharmaceutical composition thereof
CN104288142B (en) The xylocarpus granatum element H and the like purposes in preparing anti-depression drug or food
CN102406734B (en) Fructus aurantii immaturus or Fructus aurantii total flavone extract extracted by water decoction, and use thereof
CN114891018B (en) Compound 1 and compound 2 extracted from Rabdosia henryi as well as preparation method and application thereof
CN101897766B (en) Anti-inflammatory and analgesic medicine composition as well as preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090415